Action of pinaverium bromide, a calcium-antagonist, on gastrointestinal motility disorders.
1. The evidence reviewed here indicates that pinaverium bromide (Dicetel) relaxes gastrointestinal (GI) structures primarily by inhibiting Ca2+ influx through potential-dependent channels of surface membranes of smooth muscle cells. 2. The in vivo selectivity of pinaverium bromide for the GI tract appears to be due mainly to its pharmacokinetic properties. Because of its low absorption (typical for quaternary ammonium compounds) and marked hepatobiliary excretion, most of the orally-administered dose of pinaverium bromide remains in the GI tract. 3. Orally-administered pinaverium bromide does not elicit adverse cardiovascular side-effects at doses that effectively relieve GI spasm, pain, transit disturbances and other symptoms related to motility disorders. 4. Pinaverium bromide is the only Ca2(+)-antagonist with known therapeutic efficacy in the treatment of irritable bowel syndrome and certain other functional intestinal disorders.
Christen
M O
MO
R&D Department, Laboratoires de Thérapeutique Moderne, Suresnes, France.
D000818:Animals; D002118:Calcium / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015220:Calcium Channels / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D007082:Ileum / Q000187:drug effects; D009025:Morpholines / Q000494:pharmacology* / Q000627:therapeutic use; D009130:Muscle, Smooth / Q000187:drug effects*; D010276:Parasympatholytics / Q000494:pharmacology*
D015220:Calcium Channels; D009025:Morpholines; D010276:Parasympatholytics; D002118:Calcium; C013199:pinaverium